Month: September 2020

Paris, September 10th, 2020LVMH was surprised by the lawsuit filed by Tiffany against the Group in the Court of Chancery of the State of Delaware. LVMH considers that this action is totally unfounded. It has clearly been prepared by Tiffany a long time ago and communicated in a misleading way to shareholders and is defamatory. LVMH will defend itself vigorously. The long preparation of this assignment demonstrates the dishonesty of Tiffany in its relations with LVMH. This action is essentially based on the accusation by Tiffany that LVMH failed to take the reasonably necessary steps to obtain the various regulatory authorities’ approvals in a timely way. This accusation has no substance and LVMH will demonstrate this to the Delaware Court. On this matter, the filing in Brussels will take place, as expected, in the following days and this...

Paris, le 10 septembre 2020LVMH a pris connaissance avec étonnement de l’action en justice déposée contre le groupe par Tiffany devant le tribunal civil du Delaware. LVMH estime que cette action est totalement infondée. Elle est manifestement préparée de longue date par Tiffany et a été communiquée d’une manière trompeuse pour les actionnaires et diffamatoire. LVMH s’en défendra vigoureusement. La longue préparation de cette assignation montre la mauvaise foi de Tiffany dans ses relations avec LVMH. L’essentiel de cette action repose sur les reproches faits par Tiffany à LVMH de ne pas avoir agi avec diligence pour l’obtention des autorisations administratives relatives aux règles anti-trust à travers le monde. Cette accusation n’a aucune substance et LVMH le démontrera devant le tribunal civil du Delaware. A cet égard, la notification...

MISSISSAUGA, Ontario, Sept. 10, 2020 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), an award-winning life sciences innovator and exporter, is pleased to announce attainment of Australian Therapeutic Goods Administration (TGA) registration for its COVID-19 and high-risk HPV quality assessment products (QAPs™) – TGA registration of these REDx™ Controls & REDx™FLOQ® products by Microbix’s distributor, R-Biopharm, enables it to offer these workflow controls to Australian clinical labs.Specifically, R-Biopharm Pty Ltd. has attained an Australian Register of Therapeutic Goods Certificate in compliance with the relevant national Acts and Regulations. This registration permits the sale of Microbix’s positive and negative sample workflow controls in support of testing for active COVID-19 disease in...

ROCKVILLE, Md. and CHESTERBROOK, Pa., Sept. 10, 2020 (GLOBE NEWSWIRE) — Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that Michael F. Cola, President and Chief Executive Officer, will present at two upcoming virtual conferences.H.C. Wainwright 22nd Annual Global Investment ConferenceDate: Monday, September 14, 2020Time: 3:00 PM ETOppenheimer Fall Healthcare Life Sciences & MedTech SummitDate: Monday, September 21, 2020Time: 1:40 PM ETA live webcast of the presentations can be accessed under “News/Events” page in the Investors section of the Company’s website at www.cerecor.com.About CerecorCerecor is a biopharmaceutical company focused on becoming a leader in development...

NEW YORK and SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) — Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in two upcoming virtual investor conferences.Presentation Details:Event: Morgan Stanley 18th Annual Global Healthcare ConferenceDate: Thursday, September 17, 2020Time: 8:45 a.m. ETEvent: Cantor Fitzgerald Virtual Global Healthcare ConferenceDate: Thursday, September 17, 2020Time: 10:00 a.m. ETLive webcasts from the Morgan Stanley and Cantor fireside chats will be accessible through the Investors section of the Company’s website at www.zentalis.com. Following the...

NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) — Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced the appointment of William H. Carson, M.D., to its Board of Directors.“Bill knows how to drive the development of innovative treatments — including drugs for a wide range of diseases that affect the brain — from concept to commercialization,” said Francois Nader, M.D., Non-Executive Chairman of Prevail’s Board of Directors. “We are thrilled that he will bring that expertise to bear at Prevail as we continue to develop gene therapies for patients suffering from devastating neurodegenerative diseases, including Parkinson’s disease, frontotemporal dementia and Gaucher disease.”Dr. Carson was most recently...

WATERTOWN, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker, President and Chief Executive Officer, will present in two upcoming virtual conferences in September.Cantor Virtual Healthcare ConferenceDate: Tuesday, September 15Time: 4:40 PM Eastern TimeH.C. Wainwright 22nd Annual Global Investment ConferenceDate: Wednesday, September 16Time: 2:00 PM Eastern TimeA live webcast and subsequent archived replay of the presentations may be accessed via the Investors section of the Company’s website at www.eyepoint.com. The replay will be available for 90 days after the event.About EyePoint PharmaceuticalsEyePoint Pharmaceuticals, Inc. (www.eyepointpharma.com) is...

ANN ARBOR, Mich., Sept. 10, 2020 (GLOBE NEWSWIRE) — Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), a veterinary health company creating point-of-care diagnostics products for companion animals, announced today that Robert Cohen, Interim Chief Executive Officer, and Stephanie Morley, President and Chief Medical Officer, will present at the upcoming H.C. Wainwright Virtual Global Investment Conference. The presentation is scheduled for September 14, 2020 at 4:00 pm ET.The slides to be presented by Mr. Cohen and Dr. Morley will be accessible through the Investors section of the Company’s website at www.zomedica.com the morning of the presentation.About ZomedicaBased in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing...

SAN JOSE, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its financial results for the six months ended June 30, 2020.Financial Highlights for the First Six Months of 2020Total revenues were RMB4.1 million (US$0.6 million) for the first six months of 2020, an increase of 3.4% from RMB3.9 million for the first six months of 2019.Gross margin was 45.3% for the first six months of 2020, an increase of 3.9 percentage points from 41.4% for the first six months of 2019.The average selling price (“ASP”) of CDA-based tests increased by RMB228, or 114% from the first six months of 2019 to the same period of 2020 primarily due to higher pricing for new contracts and a more...